Arkadios Wealth Advisors acquired a new position in shares of DENTSPLY SIRONA Inc. (NASDAQ:XRAY - Free Report) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 74,961 shares of the medical instruments supplier's stock, valued at approximately $870,000.
Several other large investors also recently made changes to their positions in XRAY. Daiwa Securities Group Inc. increased its holdings in DENTSPLY SIRONA by 2.9% in the 4th quarter. Daiwa Securities Group Inc. now owns 26,814 shares of the medical instruments supplier's stock valued at $306,000 after purchasing an additional 767 shares in the last quarter. Blue Trust Inc. lifted its position in DENTSPLY SIRONA by 10.8% during the 1st quarter. Blue Trust Inc. now owns 12,555 shares of the medical instruments supplier's stock worth $146,000 after acquiring an additional 1,226 shares in the last quarter. Oregon Public Employees Retirement Fund boosted its holdings in DENTSPLY SIRONA by 3.3% in the 1st quarter. Oregon Public Employees Retirement Fund now owns 40,944 shares of the medical instruments supplier's stock worth $475,000 after acquiring an additional 1,300 shares during the period. Empowered Funds LLC grew its position in DENTSPLY SIRONA by 8.8% in the first quarter. Empowered Funds LLC now owns 16,324 shares of the medical instruments supplier's stock valued at $244,000 after acquiring an additional 1,320 shares in the last quarter. Finally, Wilmington Savings Fund Society FSB grew its position in DENTSPLY SIRONA by 13.0% in the fourth quarter. Wilmington Savings Fund Society FSB now owns 13,055 shares of the medical instruments supplier's stock valued at $149,000 after acquiring an additional 1,500 shares in the last quarter. Institutional investors and hedge funds own 95.70% of the company's stock.
Wall Street Analysts Forecast Growth
Several brokerages have recently weighed in on XRAY. Barclays decreased their target price on shares of DENTSPLY SIRONA from $12.00 to $9.00 and set an "underweight" rating for the company in a research note on Thursday, June 4th. Citigroup began coverage on shares of DENTSPLY SIRONA in a report on Wednesday, April 15th. They issued a "sell" rating and a $10.00 price objective on the stock. Weiss Ratings reissued a "sell (e+)" rating on shares of DENTSPLY SIRONA in a research report on Monday. Mizuho lowered their target price on DENTSPLY SIRONA from $16.00 to $14.00 and set a "neutral" rating for the company in a research note on Wednesday, May 6th. Finally, BMO Capital Markets assumed coverage on DENTSPLY SIRONA in a research note on Wednesday, July 8th. They set a "market perform" rating and a $12.00 target price for the company. Three investment analysts have rated the stock with a Buy rating, ten have given a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Hold" and an average target price of $13.46.
Get Our Latest Stock Analysis on XRAY
Insider Buying and Selling at DENTSPLY SIRONA
In other news, Director Brian P. Mckeon bought 10,000 shares of DENTSPLY SIRONA stock in a transaction on Friday, June 12th. The stock was purchased at an average cost of $10.12 per share, with a total value of $101,200.00. Following the purchase, the director directly owned 10,000 shares of the company's stock, valued at approximately $101,200. This trade represents a ∞ increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Brian T. Gladden purchased 9,985 shares of the business's stock in a transaction dated Monday, June 15th. The shares were acquired at an average cost of $10.02 per share, for a total transaction of $100,049.70. Following the acquisition, the director owned 61,849 shares of the company's stock, valued at approximately $619,726.98. The trade was a 19.25% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last three months, insiders have purchased 35,160 shares of company stock worth $351,179. 0.46% of the stock is owned by insiders.
DENTSPLY SIRONA Price Performance
Shares of XRAY opened at $13.78 on Thursday. The company has a current ratio of 1.53, a quick ratio of 0.98 and a debt-to-equity ratio of 1.52. DENTSPLY SIRONA Inc. has a 52 week low of $9.40 and a 52 week high of $14.86. The stock has a 50 day moving average of $11.68 and a 200-day moving average of $11.88. The firm has a market cap of $2.76 billion, a price-to-earnings ratio of -4.37, a PEG ratio of 1.70 and a beta of 0.85.
DENTSPLY SIRONA (NASDAQ:XRAY - Get Free Report) last issued its earnings results on Tuesday, May 5th. The medical instruments supplier reported $0.27 earnings per share for the quarter, missing analysts' consensus estimates of $0.28 by ($0.01). DENTSPLY SIRONA had a positive return on equity of 18.83% and a negative net margin of 17.06%.The business had revenue of $880.00 million for the quarter, compared to analyst estimates of $841.80 million. During the same period last year, the company posted $0.43 earnings per share. The firm's revenue for the quarter was up .1% on a year-over-year basis. As a group, analysts forecast that DENTSPLY SIRONA Inc. will post 1.42 EPS for the current year.
DENTSPLY SIRONA Profile
(
Free Report)
Dentsply Sirona Inc NASDAQ: XRAY is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.
The company's product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.
Recommended Stories
Want to see what other hedge funds are holding XRAY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DENTSPLY SIRONA Inc. (NASDAQ:XRAY - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider DENTSPLY SIRONA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DENTSPLY SIRONA wasn't on the list.
While DENTSPLY SIRONA currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.
Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
